[2] [2] BARATEAU L, PIZZA F, PLAZZI G, et al. Narcolepsy[J]. J Sleep Res, 2022, 31(4): e13631.

[3] [3] VRINGER M, ZHOU J R, GOOL J K, et al. Recent insights into the pathophysiology of narcolepsy type 1[J]. Sleep Med Rev, 2024, 78: 101993.

[5] [5] MIGNOT E, ZEITZER J, PIZZA F, et al. Sleep problems in narcolepsy and the role of hypocretin/orexin deficiency[J]. Front Neurol Neurosci, 2021, 45: 103-116.

[6] [6] LIBLAU R S, VASSALLI A, SEIFINEJAD A, et al. Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy[J]. Lancet Neurol, 2015, 14(3): 318-328.

[7] [7] SAMZADEH M, PAPU, FURTAK-NICZYPORUK M, et al. Decreased cerebrospinal fluid orexin-A (hypocretin-1) concentrations in patients after generalized convulsive status epilepticus[J]. J Clin Med, 2020, 9(10): 3354.

[8] [8] ERKEN H A, ERKEN G, GEN O, et al. Orexins cause epileptic activity[J]. Peptides, 2012, 37(1): 161-164.

[9] [9] REJDAK K, PAPU, GRIEB P, et al. Decreased cerebrospinal fluid hypocretin-1 (orexin A) in patients after repetitive generalized tonic-clonic seizures[J]. Epilepsia, 2009, 50(6): 1641-1644.

[10] [10] WANG Y Q, ZHANG M Q, LI R, et al. The mutual interaction between sleep and epilepsy on the neurobiological basis and therapy[J]. Curr Neuropharmacol, 2018, 16(1): 5-16.

[11] [11] LANIGAR S, BANDYOPADHYAY S. Sleep and epilepsy: a complex interplay[J]. Mo Med, 2017, 114(6): 453-457.

[12] [12] SUDBRACK-OLIVEIRA P, LIMA NAJAR L, FOLDVARY-SCHAEFER N, et al. Sleep architecture in adults with epilepsy: a systematic review[J]. Sleep Med, 2019, 53: 22-27.

[13] [13] QUIGG M, GHARAI S, RULAND J, et al. Insomnia in epilepsy is associated with continuing seizures and worse quality of life[J]. Epilepsy Res, 2016, 122: 91-96.

[14] [14] GOSSARD T R, TROTTI L M, VIDENOVIC A, et al. Restless legs syndrome: contemporary diagnosis and treatment[J]. Neurotherapeutics, 2021, 18(1): 140-155.

[15] [15] GEYER J D, GEYER E E, FETTERMAN Z, et al. Epilepsy and restless legs syndrome[J]. Epilepsy Behav, 2017, 68: 41-44.

[16] [16] DAUBIAN-NOS P, FRANK M K, ESTEVES A M. Sleep disorders: a review of the interface between restless legs syndrome and iron metabolism[J]. Sleep Sci, 2014, 7(4): 234-237.

[17] [17] LI Y S, YEH W C, CHANG Y H, et al. Restless legs syndrome in patients with epilepsy: risk analysis, polysomnography, and quality of life evaluation[J]. Sleep, 2024, 47(6): zsad054.

[18] [18] ZIMMER T S, DAVID B, BROEKAART D W M, et al. Seizure-mediated iron accumulation and dysregulated iron metabolism after status epilepticus and in temporal lobe epilepsy[J]. Acta Neuropathol, 2021, 142(4): 729-759.

[19] [19] DELL'AQUILA J T, SOTI V. Sleep deprivation: a risk for epileptic seizures[J]. Sleep Sci, 2022, 15(2): 245-249.

[20] [20] DALBY N O. GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors[J]. Neuropharmacology, 2000, 39(12): 2399-2407.

[21] [21] REDDY D S, CHUANG S H, HUNN D, et al. Neuroendocrine aspects of improving sleep in epilepsy[J]. Epilepsy Res, 2018, 147: 32-41.

[22] [22] BARRESE V, STOTT J B, GREENWOOD I A. KCNQ-encoded potassium channels as therapeutic targets[J]. Annu Rev Pharmacol Toxicol, 2018, 58: 625-648.

[23] [23] LI S B, DAMONTE V M, CHEN C, et al. Hyperexcitable arousal circuits drive sleep instability during aging[J]. Science, 2022, 375(6583): eabh3021.

[24] [24] SINGH N A, WESTENSKOW P, CHARLIER C, et al. KCNQ2 and KCNQ3 potassium channel genes in benign familial neonatal convulsions: expansion of the functional and mutation spectrum[J]. Brain, 2003, 126(Pt 12): 2726-2737.

[25] [25] ORHAN G, BOCK M, SCHEPERS D, et al. Dominant-negative effects of KCNQ2 mutations are associated with epileptic encephalopathy[J]. Ann Neurol, 2014, 75(3): 382-394.

[26] [26] LI X X, ZHANG Q S, GUO P P, et al. Molecular basis for ligand activation of the human KCNQ2 channel[J]. Cell Res, 2021, 31(1): 52-61.

[27] [27] LI T, WU K, YUE Z L, et al. Structural basis for the modulation of human KCNQ4 by small-molecule drugs[J]. Mol Cell, 2021, 81(1): 25-37.

[28] [28] WANG A W, YANG R Y, KURATA H T. Sequence determinants of subtype-specific actions of KCNQ channel openers[J]. J Physiol, 2017, 595(3): 663-676.

[29] [29] ZHENG Y, LIU H, CHEN Y X, et al. Structural insights into the lipid and ligand regulation of a human neuronal KCNQ channel[J]. Neuron, 2022, 110(2): 237-247.

[30] [30] LARSSON J E, KARLSSON U, WU X Y, et al. Combining endocannabinoids with retigabine for enhanced M-channel effect and improved KV7 subtype selectivity[J]. J Gen Physiol, 2020, 152(8): e202012576.

[31] [31] ELINDER F, LIIN S I. Actions and mechanisms of polyunsaturated fatty acids on voltage-gated ion channels[J]. Front Physiol, 2017, 8: 43.

[33] [33] ROUNDTREE H M, SIMEONE T A, JOHNSON C, et al. Orexin receptor antagonism improves sleep and reduces seizures in Kcna1-null mice[J]. Sleep, 2016, 39(2): 357-368.

[34] [34] KORDI JAZ E, MOGHIMI A, FEREIDONI M, et al. SB-334867, an orexin receptor 1 antagonist, decreased seizure and anxiety in pentylenetetrazol-kindled rats[J]. Fundam Clin Pharmacol, 2017, 31(2): 201-207.

[35] [35] RAZAVI B M, FARIVAR O, ETEMAD L, et al. Suvorexant, a dual orexin receptor antagonist, protected seizure through interaction with GABAA and glutamate receptors[J]. Iran J Pharm Res, 2020, 19(2): 383-390.

[36] [36] KAPLAN E H, OFFERMANN E A, SIEVERS J W, et al. Cannabidiol treatment for refractory seizures in sturge-weber syndrome[J]. Pediatr Neurol, 2017, 71: 18-23.

[37] [37] VITALE R M, IANNOTTI F A, SCHIANO MORIELLO A, et al. Identification and characterization of cannabidiol as an OX1R antagonist by computational and in vitro functional validation[J]. Biomolecules, 2021, 11(8): 1134.

[38] [38] LAVENDER I, MCGREGOR I S, SURAEV A, et al. Cannabinoids, insomnia, and other sleep disorders[J]. Chest, 2022, 162(2): 452-465.

[39] [39] MURILLO-RODRGUEZ E, MILLN-ALDACO D, PALOMERO-RIVERO M, et al. Cannabidiol partially blocks the excessive sleepiness in hypocretindeficient rats: preliminary data[J]. CNS Neurol Disord Drug Targets, 2019, 18(9): 705-712.

[40] [40] MAHONEY C E, MOCHIZUKI T, SCAMMELL T E. Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice[J]. Sleep, 2020, 43(6): zsz302.

[41] [41] HAYNES J, TALBERT M, FOX S, et al. Cognitive behavioral therapy in the treatment of insomnia[J]. South Med J, 2018, 111(2): 75-80.

[42] [42] WEI S, SMITS M G, TANG X D, et al. Efficacy and safety of melatonin for sleep onset insomnia in children and adolescents: a meta-analysis of randomized controlled trials[J]. Sleep Med, 2020, 68: 1-8.

[43] [43] BRAAM W, KEIJZER H, STRUIJKER BOUDIER H, et al. CYP1A2 polymorphisms in slow melatonin metabolisers: a possible relationship with autism spectrum disorder?[J]. J Intellect Disabil Res, 2013, 57(11): 993-1000.

[45] [45] MANOKARAN R K, TRIPATHI M, CHAKRABARTY B, et al. Sleep abnormalities and polysomnographic profile in children with drug-resistant epilepsy[J]. Seizure, 2020, 82: 59-64.

[46] [46] HALLBK T, KHLER S, ROSN I, et al. Effects of ketogenic diet on epileptiform activity in children with therapy resistant epilepsy[J]. Epilepsy Res, 2007, 77(2-3): 134-140.

[47] [47] SERAFINI A, KUATE C, GELISSE P, et al. Sleep before and after temporal lobe epilepsy surgery[J]. Seizure, 2012, 21(4): 260-265.